

## 2014 Focused Update of the CCS Guidelines for the Management of Atrial Fibrillation

### Disclosure of Conflict of Interests

Member	Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this guideline					
	Consulting fees/ Honoraria	Clinical Trials	Officer, director, or in any other fiduciary role	Ownership/ partnership/ principal	Intellectual property rights	Other financial benefit
<b>Primary Panel</b>						
Jeff Healey	Boehringer Ingelheim, St. Jude Medical	Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Medtronic, St. Jude Medical	None	None	None	None
Atul Verma	Boehringer Ingelheim, Bayer, Medtronic	Bayer, Medtronic, St. Jude Medical	None	None	None	None
John Cairns	Boehringer Ingelheim, Bayer, Pfizer	Bayer, Pfizer	None	None	None	None
Stuart Connolly	Bayer, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Medtronic, Pfizer, sanofi-aventis, St. Jude Medical	Bayer, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Johnson & Johnson, Medtronic, Pfizer, sanofi-aventis, St. Jude Medical	None	None	None	None
Jafna Cox	Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer	None	None	None	None	None
Paul Dorian	Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Servier, St. Jude Medical	None	None	None	None	None
David Gladstone	Bayer, Pfizer, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo	EMBRACE trial, principal investigator	None	None	None	None
Gordon Gubitz	Bayer, Boehringer Ingelheim	None	None	None	None	None
Noah Ivers	None	None	None	None	None	None
Kori Leblanc	Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer	None	None	None	None	Boehringer Ingelheim, educational grant to UHN Center for Innovation in Complex Care

## 2014 Focused Update of the CCS Guidelines for the Management of Atrial Fibrillation

### Disclosure of Conflict of Interests

Member	Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this guideline					
	Consulting fees/ Honoraria	Clinical Trials	Officer, director, or in any other fiduciary role	Ownership/ partnership/ principal	Intellectual property rights	Other financial benefit
Laurent Macle	Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Johnson & Johnson, St. Jude Medical	Boehringer Ingelheim, Johnson & Johnson, St. Jude Medical	None	None	None	None
Michael Sean McMurtry	None	Bristol-Myers Squibb, Pfizer, Daiichi Sankyo	None	None	None	None
L Brent Mitchell	Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Medtronic, Pfizer, St. Jude Medical	Boehringer Ingelheim, Medtronic, St. Jude Medical	None	None	None	None
Stanley Nattel	Boehringer Ingelheim, St. Jude Medical, Xention, Cardiome	AstraZeneca	None	None	None	None
Pierre Pagé	None	None	None	None	None	None
Ratika Parkash	Medtronic, St. Jude Medical	Bayer, St. Jude Medical	None	None	None	None
Paul Timothy Pollak	Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Servier	None	None	None	None	None
Allan Skanes	Bayer, Pfizer, Boehringer Ingelheim	Boehringer Ingelheim,	None	None	Cryocath/Medtronic	None
Ian Stiell	None	None	None	None	None	None
Mario Talajic	Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Medtronic	Bayer, Boehringer Ingelheim, Bristol-Myers Squibb	None	None	None	None
Teresa Tsang	Bayer, Bristol-Myers Squibb, Pfizer, Servier	None	None	None	None	None
Carl Van Walraven	None disclosed	None disclosed	None disclosed	None disclosed	None disclosed	None disclosed
<b>Secondary Panel</b>						
J Malcolm Arnold	AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Medtronic, Novartis	Abbott Vascular, Medtronic, AstraZeneca, Novartis, Boehringer Ingelheim	None	None	None	None
David Bewick	AMGEN, Merck, Boehringer Ingelheim, Pfizer, Servier	None	None	None	None	None

## 2014 Focused Update of the CCS Guidelines for the Management of Atrial Fibrillation

### Disclosure of Conflict of Interests

Member	Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this guideline					
	Consulting fees/ Honoraria	Clinical Trials	Officer, director, or in any other fiduciary role	Ownership/ partnership/ principal	Intellectual property rights	Other financial benefit
Vidal Essebag	Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Johnson & Johnson, Medtronic, Pfizer, St. Jude Medical	Boehringer Ingelheim, Johnson & Johnson, Medtronic, St. Jude Medical	None	None	None	None
Peter Guerra						
Milan Gupta	AMGEN, Bayer, Pfizer, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Merck, Eli Lilly, Otsuka, Roche, sanofi-aventis	AMGEN, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb	None	None	None	None
Brett Heilbron	Bayer, Boehringer Ingelheim, Pfizer, sanofi-aventis	None	None	None	None	None
Charles Kerr	None disclosed	None disclosed	None disclosed	None disclosed	None disclosed	None disclosed
Paul Khairy	None disclosed	None disclosed	None disclosed	None disclosed	None disclosed	None disclosed
Bob Kiaii	Medtronic	None	None	None	None	None
George Klein	Boston Scientific, Medtronic	None	None	None	None	None
Simon Kouz	AstraZeneca, Medtronic, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Novartis, Ostuka, Pfizer, Servier, sanofi-aventis	AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Johnson & Johnson, Otsuka, Pfizer, Roche, sanofi-aventis, Servier	None	shareholders: Medtronic, Johnson & Johnson, AstraZeneca, Novo, Boston Scientific	None	None
Peter Lin	None disclosed	None disclosed	None disclosed	None disclosed	None disclosed	None disclosed
Jan Surkes	Bayer, Boehringer Ingelheim	None	None	None	None	None
D. George Wyse	None	Boehringer Ingelheim, Boston Scientific, Medtronic, Bristol-Myers Squibb, Pfizer, sanofi-aventis	None	None	None	None